Video
Predictive Intelligence: The Secret Weapon in Pharma BD Assessment
With pharma M&A activity surging and billions on the line, the difference between winning and losing deals often comes down to speed and insight. How do you cut through incomplete data and tight timelines to identify the right opportunities before your competitors do? Learn more in this discussion with Dr. Jakub Pijewski, VP of US Commercial Strategy, BD and External Collaborations at GSK, along with experts from Veeva and Verix.
Hear how predictive intelligence is transforming BD assessment by:
- helping teams move from reactive searching to proactive evaluation
- providing a data-driven framework that quickly translates vast data into actionable insights
- reducing assessment time by 10X (from about 6 weeks to under a week) and delivering a 50% reduction in cost per assessment
Learn more about Veeva Compass Patient.